1652.HK WACC - Weighted Average Cost of Capital

The WACC of Fusen Pharmaceutical Co Ltd (1652.HK) is 7.9%.

The Cost of Equity of Fusen Pharmaceutical Co Ltd (1652.HK) is 13.15%.

The Cost of Debt of Fusen Pharmaceutical Co Ltd (1652.HK) is 6.00%.

	Range	Selected
Cost of equity	11.30% - 15.00%	13.15%
Tax rate	16.80% - 21.30%	19.05%
Cost of debt	5.00% - 7.00%	6.00%
WACC	6.8% - 9.0%	7.9%

WACC

1652.HK WACC calculation

Category	Low	High

Long-term bond rate	2.9%	3.4%
Equity market risk premium	6.0%	7.0%
Adjusted beta	1.41	1.59

Additional risk adjustments	0.0%	0.5%
Cost of equity	11.30%	15.00%

Tax rate	16.80%	21.30%
Debt/Equity ratio	1.69	1.69
Cost of debt	5.00%	7.00%

After-tax WACC	6.8%	9.0%


Selected WACC	7.9%

1652.HK's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 1652.HK:

cost_of_equity (13.15%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (1.41) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.